Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists · 2026
Clinical Approach to the Care of Patients With Recurrent Differentiated Thyroid Cancer: A Focus on Papillary Thyroid Carcinoma.
СтатьяОбзорНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Roman-Gonzalez Alejandro, Sanabria Alvaro, Agosto-Salgado Sarimar
Аннотация
OBJECTIVE: To provide a clinically oriented framework for the evaluation and management of recurrent papillary thyroid carcinoma (PTC), integrating updated risk stratification and contemporary therapeutic strategies.
METHODS: A narrative review of recent evidence, including the 2025 American Thyroid Association (ATA) recommendations, was conducted, focusing on risk stratification models, diagnostic pathways, and therapeutic approaches for recurrent and metastatic disease.
RESULTS: Recurrent PTC represents a heterogeneous clinical entity that requires individualized management. The 2025 ATA guidelines introduce a four-tier recurrence risk model and the DATA framework (Diagnosis, Assessment, Treatment, and Assessment of response), enabling structured clinical decision-making. Management strategies range from active surveillance for low-volume disease to locoregional therapies such as surgery and image-guided ablation in selected cases. In advanced or progressive disease, systemic targeted therapies, ideally guided by molecular profiling, play a central role. Integration of clinical, pathological, and molecular factors is essential to optimize treatment selection and balance disease control with treatment-related morbidity.
CONCLUSIONS: Management of recurrent PTC requires a dynamic, risk-adapted, and multidisciplinary approach. Implementation of the ATA 2025 framework, combined with molecularly informed therapeutic strategies, allows personalized care and may improve long-term outcomes in both locoregional and metastatic disease.
METHODS: A narrative review of recent evidence, including the 2025 American Thyroid Association (ATA) recommendations, was conducted, focusing on risk stratification models, diagnostic pathways, and therapeutic approaches for recurrent and metastatic disease.
RESULTS: Recurrent PTC represents a heterogeneous clinical entity that requires individualized management. The 2025 ATA guidelines introduce a four-tier recurrence risk model and the DATA framework (Diagnosis, Assessment, Treatment, and Assessment of response), enabling structured clinical decision-making. Management strategies range from active surveillance for low-volume disease to locoregional therapies such as surgery and image-guided ablation in selected cases. In advanced or progressive disease, systemic targeted therapies, ideally guided by molecular profiling, play a central role. Integration of clinical, pathological, and molecular factors is essential to optimize treatment selection and balance disease control with treatment-related morbidity.
CONCLUSIONS: Management of recurrent PTC requires a dynamic, risk-adapted, and multidisciplinary approach. Implementation of the ATA 2025 framework, combined with molecularly informed therapeutic strategies, allows personalized care and may improve long-term outcomes in both locoregional and metastatic disease.